By targeting the immune checkpoint in TME, anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4), anti-programmed cell death 1 (PD-1), and anti-CD274/PD-L1havebeen shown to be the most effective immunotherapy methods for cancer [7,8]. Here, CTLA4 is linked to cancer.